578729-18-7

Usage

InChI:InChI=1/C8H6FIN4/c1-14-12-8(11-13-14)7-5(9)3-2-4-6(7)10/h2-4H,1H3

Upstream product

• 79544-29-9 2-fluoro-6-iodobenzonitrile 
• 578729-17-6 5-(2-fluoro-6-iodophenyl)-2H-tetrazole 
• 74-88-4 methyl iodide 
• 578729-17-6 5-(2-fluoro-6-iodo-phenyl)-1H-tetrazole 

Downstream Products

• 578729-19-8 (1-{1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)-biphenyl-4-yl]-ethylcarbamoyl}-cyclopropyl)-carbamic acid tert-butyl ester 
• 1048975-85-4 {1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)-biphenyl-4-yl]-ethyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula I, (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists

A series of biphenylaminocyclopropane carboxamide based bradykinin B 1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in t

2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives

Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives

N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.